Linkedinx Youtube News Today

Simulations Plus, Inc. , a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that Shawn...

Predicting DILI risk supports informed decision-making regarding drug evaluations and approvals ...

Total revenue of $18.3 million and diluted earnings per share of $0.20 Maintains full-year revenue guidance of $66 to $69 million and EPS guidance of $0.66 to $0.68 ...

Simulations Plus, Inc. ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024....

Simulations Plus, Inc. , a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Shawn O’Connor, chief executive officer,...

Research project with NIEHS includes focus on qualification of in silico methods for prioritization, assessment of risk, and identification of safety margins for chemical use ...